Koen Sandra

home / authors / koen-sandra

Koen Sandra is the editor of “Biopharmaceutical Perspectives”. He is CEO at RIC group and visiting professor at Ghent University. He is also a member of LCGC Europe’s editorial advisory board.

Articles

HPLC to UHPLC Transfer of USP Method for Amlodipine Besylate

Gerd Vanhoenacker;Pat Sandra;Koen Sandra;Frank David;Mieke Steenbeke;Agilent Technologies, Inc.;Udo Huber

April 25th 2016

This Application Note describes the method transfer of a USP HPLC method for amlodipine besylate tablets to a UHPLC method using the Agilent 1290 Infinity II LC.

Advances in Biopharmaceutical Analysis

Pat Sandra;Koen Sandra

October 2nd 2015

Advances in Biopharmaceutical Analysis

Analyzing Host Cell Proteins Using Off-Line Two-Dimensional Liquid Chromatography–Mass Spectrometry

Pat Sandra;Koen Sandra;Alexia Ortiz

October 2nd 2015

Analyzing Host Cell Proteins Using Off-Line Two-Dimensional Liquid Chromatography–Mass Spectrometry

Monoclonal Antibodies and Biosimilars — A Selection of Analytical Tools for Characterization and Comparability Assessment

Isabel Vandenheede;Pat Sandra;Koen Sandra;Emmie Dumont

October 2nd 2015

With the top-selling mAbs evolving out of patent there has been a growing interest in the development of biosimilars. In demonstrating comparability to the originator product, biosimilar developers are confronted with an enormous analytical challenge. This article presents a selection of state-of-the-art analytical tools for mAb characterisation and comparability assessment.

The Power of Liquid Chromatography–Mass Spectrometry in the Characterization of Protein Biopharmaceuticals

Isabel Vandenheede;Koen Sandra;Pat Sandra

May 2nd 2013

This article highlights some selected examples of the power of liquid chromatography combined with mass spectrometry (LC–MS) in the development of protein biopharmaceuticals.